������Ƶ

Heat therapy could offer a novel nonpharmacologic approach for treating the overnight hypertension that affects patients with autonomic failure.

A white blood cell, the TREM2/APOE/C1Q-positive macrophage, has been identified as a potential biomarker to predict recurrence of the most common type of kidney cancer and as a possible target for drug development.

Vanderbilt neonatology team pinpoints signaling pathways involved in the progressive lung fibrosis that occurs in rare genetic diseases.

Vanderbilt researchers dissected the complex microenvironment of the pancreatic islet to discover the signals that drive beta cell regeneration — as a possible treatment for diabetes.

People with a high polygenic risk score for colorectal cancer could benefit more at preventing the disease by leading healthy lifestyles than those at lower genetic risk, according to a study by Vanderbilt researchers published in the April issue of The American Journal of Clinical Nutrition.

Cancer specialists at Vanderbilt University Medical Center, in partnership with biochemists and structural biologists across the Vanderbilt University campus, are taking “personalized” cancer therapy to a new level.

Tumors consume glucose at high rates, but a team of Vanderbilt researchers has discovered that cancer cells themselves are not the culprit, upending models of cancer metabolism that have been developed and refined over the last 100 years.

The Vanderbilt Institute for Clinical and Translational Research (VICTR) has been awarded a major federal grant to lead a national trial of treatments targeting the Renin Angiotensin Aldosterone System (RAAS) in patients hospitalized with COVID-19.

A protein implicated in neurodegenerative diseases including amyotrophic lateral sclerosis prevents the activation of an innate immune response that leads to cell death, Vanderbilt researchers have discovered.

Vasorelaxing peptides could offer a promising therapeutic strategy for reducing the neurological deficits caused by subarachnoid hemorrhage-induced cerebral blood vessel constriction.

Voluntary data sharing across a region’s health systems and ambulatory care practices is important for measuring and improving health care quality and safety, Vanderbilt researchers report.

A more comprehensive, equitable approach to researching gun violence can lead to better policy solutions. Read More

Triple-negative breast cancer cells engage in a “glutamine steal” — outcompeting T cells for the nutrient glutamine and impairing their ability to kill tumor cells, Vanderbilt researchers have discovered.

The remarkable success of the COVID-19 vaccines began in a Vanderbilt lab decades ago, with the groundbreaking research of alumnus Dr. Barney Graham. Read More

The U.S. Centers for Disease Control and Prevention (CDC) has awarded Vanderbilt University Medical Center a two-year, $3.7-million contract to determine genetic and bacterial factors that may increase the risk for severe illness and death from COVID-19.

A novel hormone deficiency may exist in humans, Vanderbilt investigators have discovered. In an analysis of two decades worth of electronic health records, the researchers found that some patients have unexpectedly low levels of natriuretic peptide hormone in clinical situations that should cause high levels of the hormone.

Strong, collaborative relationships with principal investigators are a key factor of longevity in clinical research coordinator positions — an essential, but increasingly transient job in executing treatment-advancing clinical trials, Vanderbilt University Medical Center researchers found.

The emergence of pathogenic skin fungi that cause the disease chytridiomycosis is contributing to the global loss of amphibian populations. 

A monoclonal antibody “cocktail” developed at Vanderbilt University Medical Center to neutralize the COVID-19 virus is effective against all known strains, or variants, of the virus, according to a report published today in the journal Nature Medicine....

Evotec, a drug company headquartered in Hamburg, Germany, has begun a phase 1 clinical trial of a monoclonal antibody against the chikungunya virus that was identified at Vanderbilt University Medical Center.